Perrigo Company (NYSE:PRGO; TASE:PRGO) CEO Joseph Papa is ready to talk with Mylan N.V. (MYL) about its takeover bid, but at a higher price. The rival drugmaker’s present bid is nowhere near there.
Perrigo last month rejected Mylan’s offer of $75 in cash and 2.3 Mylan shares for each Perrigo share, which had a value of about $32.7 billion.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
At the same time, Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has offered to acquire Mylan for more than $40 billion on condition that the Mylan-Perrigo deal does not go ahead.
“We’re pretty far apart, ” Perrigo CEO Joseph Papa said Monday at an investor meeting hosted by UBS AG in New York, where he gave a presentation and spoke to investors during a smaller session. “We believe they have substantially undervalued the company.”
UBS published a summary of Papa’s speech in which he said that Mylan “substantially undervalued the company.” In addition, he said that Mylan’s rate of growth and profit multiple would lead to a dilution for Perrigo’s shareholders. Papa added that the ROIC (return on investment capital) from the deal was not attractive and that if Perrigo decided to consider Mylan’s offer, he would also discuss the matter with other potential buyers to achieve the best returns for shareholders.
UBS said that in the long term Perrigo could achieve organic growth of 5-10% while continuing to seek non-organic growth opportunities.
Mylan has said it plans to go directly to Perrigo’s shareholders with an offer. That could happen by Sept. 14, Papa said at the conference. Perrigo doesn’t plan to use a poison pill to try to block such an offer.
